


## Tildacerfont

## Chemical Properties

CAS No. :	1014983-00-6
Formula:	C <sub>20</sub> H <sub>26</sub> ClN <sub>5</sub> O <sub>5</sub>
Molecular Weight:	419.97
Storage:	Keep away from direct sunlight, Store under nitrogen Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



## Biological Description

Description	Tildacerfont is an antagonist of CRF1 and reduces the levels of adrenocorticotrophic hormone and adrenal androgen. Tildacerfont can be used in studies about congenital adrenal hyperplasia.
Targets(IC50)	CRFR

## Solubility Information

Solubility	DMSO: 4.2 mg/mL (10 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3811 mL	11.9056 mL	23.8112 mL
5 mM	0.4762 mL	2.3811 mL	4.7622 mL
10 mM	0.2381 mL	1.1906 mL	2.3811 mL
50 mM	0.0476 mL	0.2381 mL	0.4762 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

- Zorrilla EP, Logrip ML, Koob GF. Corticotropin releasing factor: a key role in the neurobiology of addiction. *Front Neuroendocrinol.* 2014 Apr;35(2):234-44.
- Prete A, et al. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. *Eur J Endocrinol.* 2021; 186(1):R1-R14. Published 2021 Nov 30.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481